Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie

This article was originally published in The Pink Sheet Daily

Executive Summary

The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.

You may also be interested in...

ImmunoGen Hopes T-DM1 Hype Shines Light On Internal Efforts

The anticipated success of the recently filed T-DM1 has offered ImmunoGen the opportunity to shine a light on its own ADC efforts.

Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates

Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.

Celtic Therapeutics Earmarks $50M For ADC Therapeutics

Private equity firm Celtic Therapeutics is promising a $50 million investment in ADC Therapeutics, a new company that will work closely with Celtic’s other investment Spirogen on antibody-drug conjugates.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts